Today we’re proud to announce the formation of the Tilray Medical Advisory Board, an internationally recognized group of researchers and physicians who are committed to facilitating groundbreaking advancements in the emerging field of cannabinoid science. The Board will meet regularly to evaluate opportunities for medical cannabis research and serve as a strategic resource for Tilray as the Company establishes partnerships with world-leading hospitals and universities to conduct clinical trials evaluating the potential therapeutic benefits of cannabinoid-derived medicines globally.

“As public interest in cannabis-derived medicines continues to grow, we need objective, valid data about the potential risks and benefits of medical cannabis gathered through clinical trials and the scientific method,” said Orrin Devinsky, Chairman of the Advisory Board. Dr. Devinsky was the lead investigator for the first study approved by the U.S. Food and Drug Administration to evaluate the efficacy of a cannabis-based drug in epilepsy in children.

“Clinical research is critical to furthering our understanding of how patients might use cannabinoid-based medicines to treat a range of symptoms and conditions, including pain, epilepsy, and symptoms associated with cancer.” said Tilray Clinical Research Director Catherine Jacobson. “The Medical Advisory Board consists of experts in these fields, and we are excited to partner with them to advance scientific knowledge of medicines consisting of extracted cannabinoids.”

Inaugural members of the Medical Advisory Board include:
  • Orrin Devinsky, MD, Chairman, is Director of the Comprehensive Epilepsy Center at the New York University (NYU) Langone Medical Center. His research interests include the use of cannabinoids and other medications to treat a variety of epilepsy syndromes.
  • Praveen Anand, MD, is Head of the Centre for Clinical Translation and Professor of Clinical Neurology at Imperial College London. His research focuses on pathophysiological and molecular mechanisms in the human sensory neuropathies and chronic pain syndromes.
  • Abraham Chachoua, MD, is Associate Director of Cancer Services at the NYU Langone Perlmutter Cancer Center and the Jay and Isabel Fine Professor of Oncology at the NYU Langone Department of Medicine. He specializes in the treatment of cancers that affect the lungs and chest.
  • Elizabeth K. Hale, MD, is a Clinical Associate Professor of Dermatology at NYU Langone Medical Center and the co-Founder of CompleteSkinMD in New York City. She specializes in laser surgery and cosmetic dermatology.
  • Catherine Lord, PhD, is Professor of Psychology in Psychiatry and founding Director of the Center for Autism and the Developing Brain (CADB), at New York-Presbyterian Hospital, Weill Cornell Medicine, Columbia University College of Physicians and Surgeons in collaboration with New York Collaborates for Autism.
Tilray is committed to advancing the science and safety of medical cannabis products by supporting clinical research. The company is currently partnering with hospitals and universities to supply three clinical trials, focused on pediatric epilepsy at Toronto SickKids Hospital, post-traumatic stress disorder at the University of British Columbia, and chemotherapy-induced nausea and vomiting at the University of Sydney in Australia.